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Summary
Objective: Sporadic Crimean-Congo hemorrhagic fever (CCHF) cases were first reported in
Turkey in 2002, arising particularly in northeastern Anatolia. Epidemics have been reported in
neighboring countries since the 1970s. With the increase in number of CCHF virus infected or
suspected cases in the Aydin region of western Anatolia by 2006, we decided to focus attention on
this disease.
Methods: Twenty-six patients with an acute febrile syndrome characterized by malaise, bleed-
ing, leukopenia, and thrombocytopenia were admitted to various hospitals in Aydin between May
2007 and June 2008. CCHF diagnosis was established by measuring IgM in a blood sample and/or
detecting viral genome by real-time polymerase chain reaction (real-time PCR) or by clinical
findings of the disease, even if IgM was negative (real-time PCR was not performed).
Results: Twenty-five patients (22 of the patients with cases confirmed by laboratory findings)
matched the criteria for CCHF defined by the European Network for Diagnostics of ‘Imported’
Viral Diseases (ENIVD); one patient did not match suspected-case criteria, however he was also
included in the study as his blood sample was positive according to real-time PCR. The most
common signs and symptoms encountered were fever, myalgia, nausea, and vomiting. The overall
case-fatality rate was 5.5% (one patient) in 2007. Patients showed hemorrhagic manifestations
(35%), while complete blood counts revealed thrombocytopenia and leukopenia in 17 patients
(65%), and raised levels of aspartate aminotransferase (77%), alanine aminotransferase (77%),
lactate dehydrogenase (69%), and creatinine phosphokinase (42%).
Conclusions: To date, western Anatolia has been accepted as a non-endemic area for this
disease, with only sporadic cases. These non-endemic CCHF cases in Aydin province of the
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Aegean region should alert other non-endemic regions of the world to be mindful of this
disease.
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Crimean-Congo hemorrhagic fever (CCHF) is a potentially
fatal viral infection occurring in about 30 countries world-
wide. It has the most extensive geographic range among the
significant tick-borne viruses.1,2 The virus belongs to the
genus Nairovirus in the Bunyaviridae family and causes
severe disease in humans, with a reported mortality rate
of 5—80%.3 The widespread geographic distribution of CCHF
virus and its ability to produce severe human disease with
high mortality rates make the virus an important human
pathogen. Humans become infected through tick bites or
direct contact with body fluids or tissues from viremic
patients or viremic livestock.1,2,4,5
CCHF cases were first reported in Turkey in 2002, although
epidemics have been reported from neighboring countries
since the 1970 s.1,2,4,6—9 Recently, a case report from Greece
was published.10 Between 2002 and 2007, a total of 1820
confirmed cases were reported to the Ministry of Health
(MoH) of Turkey.11 The diagnoses of these cases were per-
formed through virus detection by PCR or IgM and/or IgG
positivity on ELISA. All these patients were hospitalized, and
the fatality rate was calculated as 5.3%. A great majority of
the cases were seen in northeastern Anatolia (Tokat, Sivas,Figure 1 Endemic provinces andGu¨mu¨shane, Amasya, Yozgat and Corum provinces;
Figure 1).12 Western Anatolia and the Aegean region including
Aydin is accepted as a non-endemic area (Figure 1).13,14 By
2006, CCHF cases began to be recorded in Aydin. The cases
reported in Aydin were all residents of the city and surround-
ings. Since Aydin is an important agricultural and tourism
zone of Turkey showing an increase in CCHF cases, we
decided to make a detailed analysis of this area.
Patients and methods
Patients
This was a retrospective descriptive study carried out
between May 2007 and June 2008. A CCHF case report form,
prepared by the MoH of Turkey, was filled out for all patients
admitted for tick bites and/or suspicious cases as defined by
the European Network for Diagnostics of ‘Imported’ Viral
Diseases (ENIVD).15 Admission date, age, gender, address,
existing symptoms, epidemiological history, physical exam-
ination, and laboratory findings were recorded. Cases
admitted for tick bites without any symptoms and normal
laboratory findings were informed about CCHF and its con-
sequences. They were advised to follow up their own bodyAydin on the map of Turkey.
Table 1 Demographic and clinical characteristics of the
patients
Patients (%) (N = 26)
Males 15 (58)
Died 1 (5.5)a
History of tick bite 19 (73)
Living environment
Urban 11 (42)
Rural 15 (58)
Symptoms and signs
Fever 24 (92)
Headache 18 (69)
Myalgia 15 (58)
Abdominal pain 11 (42)
Nausea 18 (69)
Vomiting 12 (46)
Diarrhea 9 (35)
Hemorrhagic manifestations 9 (35)
Abnormal laboratory results
AST—ALT elevation 20 (77)
LDH elevation 18 (69)
Leukopenia 17 (65)
Thrombocytopenia 17 (65)
CK elevation 11 (42)
AST, aspartate aminotransferase; ALT, alanine aminotransferase;
LDH, lactate dehydrogenase; CK, creatinine phosphokinase.
a The percentage is calculated based on 18 patients in 2007.
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of any symptoms related to the disease (i.e., fever over
38 8C, petechiae, hemorrhage without history of trauma).
These cases were also reached by telephone call from the
community health centers. Those with symptoms were hos-
pitalized immediately in city hospitals. Similar forms were
filled out for patients who were diagnosed with CCHF at other
health centers in the city. Cases positive for CCHF virus IgM
and/or positive real-time polymerase chain reaction (real-
time PCR) or cases negative for IgM (real-time PCR not
performed) but showing clinical findings of the disease (acute
febrile syndrome characterized by malaise, bleeding, leuko-
penia, and thrombocytopenia) were included in the study.
Cases whose blood samples were unavailable or cases who
had no clinical and laboratory findings were excluded from
the study.
Laboratory testing
Patient venous blood samples were stored in optimal condi-
tions and sent to the Turkish MoH Refik Saydam National
Hygiene Center for confirmation of the diagnosis.
TaqMan-based real-time PCR was performed as described
by Yapar et al.16 Five microliters of viral RNA were added to
20 ml of the mixture containing 5 pmol of each primer, 4 pmol
of TaqMan probe, 0.2 mM of each dNTP (containing dUTP),
and 6 mM MgCl2. The cycle conditions were carried out as
follows: a cycle of real time at 42 8C for 40 min, 95 8C for
10 min, followed by 40 PCR cycles of 15 s at 95 8C, 1 min at
60 8C . The assay was run on a Perkin—Elmer 7700 Sequence
Detection System using the combination of reverse transcrip-
tase (MBI Fermentas) and Hot Start Taq DNA polymerase
(Bioron GmbH, Germany). The data were analyzed according
to Yapar et al.16
CCHF IgM ELISA testing was performed at the Refik Saydam
National Hygiene Center, Virology Research and Reference
Laboratory following the recommendations of the Centers for
Disease Control and Prevention (CDC, Atlanta, USA). CCHF
IgM was detected by ELISA prepared with inactivated native
CCHF viral antigens (Strain IbAr 10200) grown in Vero E6 cells
on serum samples.17
Results
Venous blood samples were collected from 61 patients, 49 of
them in 2007 and 12 in 2008. Among the samples taken, ELISA
tests for specific CCHF IgM antibodies were positive for eight
patients, and real-time PCR tests for CCHF were positive in
14. IgM was negative in four patients and real-time PCR was
not performed on the blood samples of these cases; however,
clinical findings in these patients (acute febrile syndrome
characterized by malaise, bleeding, leukopenia, and throm-
bocytopenia) were concordant with CCHF. Thus, 26 patients
were enrolled in the study. Twenty-five (96%) in 26 patients
fulfilled the suspected-case criteria for CCHF of the ENIVD.15
Only one patient did not match the suspected-case criteria,
though he was also included in the study as real-time PCR
analysis of his blood sample was positive, confirmed by
repeat analyses. Of these 26 patients, 18 were admitted
to various hospitals in Aydin between April and September
2007 and eight patients between May and June 2008. All caseswere indigenous—autochthonous with no history of traveling
to another CCHF endemic area (e.g., eastern Anatolia) in
Turkey.
Fifteen patients were male and 11 were female. The
mean  SD age was 30.7  20.6 years (range 2—69 years).
Three (12%) of the patients were in the pediatric age group
(0—15 years old). Themost commonly encountered signs and
symptoms were fever, headache, myalgia, nausea, and
vomiting. Hemorrhagic manifestations were seen in nine
(35%) patients. Demographic and clinical characteristics
of the patients are shown in Table 1. The time period
between the onset of symptoms and referral to hospital
was 3 days on average (range 1—10 days). Eleven patients
(42%) were admitted on the day the symptoms appeared.
The mean  SD hospitalization was 8.8  4.2 days (range 2—
17 days).
Seventeen (65%) of the 26 patients had received ribavirin
therapy. The overall case-fatality rate was 5.5% (one patient)
in 2007. The fatality was a 53-year-old woman who had had a
tick extracted from her neck. She had presented to the
hospital on the 10th day after symptoms had arisen. She
had received therapy (ribavirin and conventional, i.e., blood
transfusion, etc.), but died on the second day of hospitaliza-
tion due to disseminated intravascular coagulopathy.
Thrombocytopenia and leukopenia were seen in 17 (65%)
patients (Table 1). The results of laboratory tests performed
at the time of admission to the hospital are shown in Table 2.
Table 2 Laboratory findings in patients at admission
Patient mean (min—max) SD
AST (U/L) 351.3 (17—3196) 667
ALT (U/L) 164.3 (13—931) 230.6
LDH (U/L) 684.1 (103—3301) 766.3
CK (U/L) 669.2 (8—4474) 1178.1
Platelet count
( 109/l)
136.9695 (11.000—407.000) 102.3365
WBC count
( 109/l)
4.8443 (0.800—17.900) 4.72279
SD, standard deviation; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; LDH, lactate dehydrogenase; CK, crea-
tinine phosphokinase; WBC, white blood cell.
e434 B. Ertugrul et al.Discussion
There has been a substantial increase in reports of CCHF virus
over the past 10 years. CCHF virus-infected cases were first
reported in Turkey in 2002 and the number of cases has
gradually increased.3,18—20 The Turkish MoH handles the dis-
ease as an important public health problem, since for the last
four years CCHF has been endemic in northeastern Anatolia.
According to previous studies, northwestern Anatolia and the
province of Aydin and its surroundings are accepted as non-
endemic for CCHF.3,13,18—24
In 2006 blood samples were taken from cases mimicking
CCHF infection in Aydin province; three of 14 blood samples
serologically confirmed a diagnosis of CCHF. This could be
taken as a signal of a potential widespread threat in our
region. The Department of Infectious Diseases and Clinical
Microbiology of Adnan Menderes University Medical Faculty
together with the local health authorities have performed an
informative study for the medical staff and the residents in
this area. A public awareness campaign was launched, which
included brochures, TV programs, and employee education
programs on public health about early diagnosis and preven-
tive measures concerning tick bites and CCHF infections.
Following this campaign, people began to present at
health centers immediately following any tick bite. We
determined that there was no admission for tick bite in
2006, but 1724 tick bite admissions were observed in 2007,
with a further 1380 in the first half of 2008. Whether or not
there was a history of existing tick bite, patients with
complaints of the disease were admitted to health centers
in 2007 and 2008, andwere hospitalized in infectious diseases
and clinical microbiology clinics of the state and university
hospitals.
This is the first time that so many cases have been
reported outside of the regions accepted as endemic. Does
this mean that the disease in Turkey is spreading towards the
west? It is hard to answer ‘yes’, since the disease has not been
observed in the surrounding provinces, with the exception of
sporadic cases. The ratio of agrarian in Aydin to the popula-
tion of surrounding provinces is higher than in the surrounding
provinces, and some geographical characteristics of this area
are similar to those of endemic regions. The common geo-
graphical characteristic of regions where cases are diffusely
observed is fragmental land with a combination of forestry
and agricultural sections. Changes in climatic conditions havebeen suggested to be one of the factors that has facilitated
reproduction of the tick population, and consequently the
increased incidence of tick-borne infectious diseases.1 The
number of days with a temperature of over 5 8C in April, and
the daily mean temperature in April in the region of Turkey
affected by a recent outbreak were reported to be increased
in the years before the outbreak.25 The temperature levels in
summer in Aydin resemble those of endemic regions where it
is hot and arid. The mean temperature of Aydin in July is
about 26.8 8C, while it is about 24.2 8C in eastern Anatolia.26
The potential roles of migratory birds and the movement of
livestock carrying ticks in the spread of the virus over distant
geographic areas have been studied.1 Birds migrating from
the Balkans were suggested to be the cause of the 2002
outbreak in Turkey.18 The Aydin region is on the migration
route of migratory birds.
Both the climatic and geographic characteristics provide
the appropriate environment for ticks to reproduce,27 and
these vectors spread to rural areas involved with agriculture
via cattle, sheep, goats and small mammals such as hedge-
hogs, hares, and rodents. Residents in these areas work in
fields in the summer, a time when the ticks are in their
mature form and may be actively transferred to them by
these animals. Following the campaign carried out in the
Aydin region, admission to healthcare centers particularly
increased in the summer months. As a consequence, the
identification of infected patients has increased the recogni-
tion of this disease, and contrary to common belief it is
concluded that the disease has been observed in our region,
but could not have been recognized before.
This study is important for people visiting the region.
Aydin is one of the important tourism centers in the Aegean
region of western Anatolia, which had a population of about
one million including the surrounding area in the year 2007.
Every year, over one million tourists visit the region for its
historic towns and sea tourism. To date, no CCHF cases have
been reported from the popular tourist resorts in this area
and the Aegean coast. The European Centre for Disease
Prevention and Control advises travelers to affected areas
to take general preventive measures to minimize exposure to
tick bites, and people who have traveled to this area having
symptoms after a tick bite are advised to contact their
physician.28 When suspected symptoms are observed in tra-
velers on return to their home countries, CCHF should be
considered in the differential diagnosis whether there is a
history of tick bite or not. There are case reports and studies
supporting this opinion.29,30
Although there is different information in the literature
related to treatment with ribavirin, both the World Health
Organization and the Turkish MoH recommend this treat-
ment. Therefore, ribavirin was administered to 17 patients
with CCHF at the time of admission in 2007. However, one of
our cases was admitted to a health service for tick bite, but
since clinical and laboratory findings were not concordant
with CCHF, he was discharged home after the tick was
extracted and advised to follow-up his body temperature.
As his blood sample showed a positive result with real-time
PCR (one day later), he was recalled. On second evaluation,
he had no findings related with the disease and was consid-
ered as asymptomatic and did not receive ribavirin treat-
ment. There is very little information showing that the
diseasemay be asymptomatic.31,32 Generally, there are three
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and severe.31,33 This case showed that there may be asymp-
tomatic cases and this issue should be taken into considera-
tion.
There are different ratios related with the mortality rate
of the disease. The case-fatality rate has been estimated to
range from 5% to 80% in various studies.34,35 The mean
mortality rate is between 20% and 50%. In studies performed
in our country, mortality rates range between 5% and
20%.3,18,19,33,36 This wide difference in mortality rates may
be attributed to the infecting virus type (up to eight clades of
CCHF virus have been observed worldwide) and patient care
conditions.1,18 The mortality rate in our cases was 5.5% in
2007, which correlates with other figures from Turkey. This
low mortality rate might be due to the early admission of
cases to hospitals and having supplementary treatment in the
early stages of the disease.
The present study had several limitations. The first was its
retrospective nature, which was dependent on the case
report forms of the MoH. These forms did not include infor-
mation on the severity of clinical presentation and therefore
severity classification could not be performed. Since hemo-
globin, prothrombin time, partial thromboplastin time, and
bilirubin levels of all cases were not available, these values
could not be included. Secondly, virus sequencing was not
performed, so further studies are needed for genetic char-
acterization of the strain. Another limitation was that there
was no agreement between hospitals with regard to the
protocols for ribavirin treatment, hence treatment criteria
are not given.
Conclusions
This study emphasizes the widespread geographic distribu-
tion of CCHF virus, as it reports cases from a non-endemic
region (Aydin). The similarity between natural environmen-
tal conditions and climatic properties of Aydin and endemic
areas should be a warning to other non-endemic regions with
the same characteristics. Therefore, disease-related cam-
paigns should be carried out to help recognize potentially
missed cases. Furthermore, as Aydin is one of the most
popular tourism places in the world, entertaining over one
million tourists every summer, this study should be a refer-
ence for the authorities in tourism.
Conflict of interest: No conflict of interest to declare.
References
1. Ergonul O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis
2006;6:203—14.
2. Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res
2004;64:145—60.
3. Ergonul O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H.
Characteristics of patients with Crimean-Congo hemorrhagic
fever in a recent outbreak in Turkey and impact of oral ribavirin
therapy. Clin Infect Dis 2004;39:284—7.
4. Izadi S, Naieni KH, Madjdzadeh SR, Nadim A. Crimean-Congo
hemorrhagic fever in Sistan and Baluchestan Province of Iran, a
case—control study on epidemiological characteristics. Int J
Infect Dis 2004;8:299—306.
5. Khan AS, Maupin GO, Rollin PE, Noor AM, Shurie HH, Shalabi AG,
et al. An outbreak of Crimean-Congo hemorrhagic fever in theUnited Arab Emirates, 1994—1995. Am J Trop Med Hyg
1997;57:519—25.
6. Al-Tikriti SK, Al-Ani F, Jurji FJ, Tantawi H, Al-Moslih M, Al-Janabi
N, et al. Congo/Crimean haemorrhagic fever in Iraq. Bull World
Health Organ 1981;59:85—90.
7. Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral
ribavirin in the treatment of Crimean-Congo hemorrhagic fever
in Iran. Clin Infect Dis 2003;36:1613—8.
8. Papa A, Bino S, Llagami A, Brahimaj B, Papadimitriou E, Pavlidou
V, et al. Crimean-Congo hemorrhagic fever in Albania, 2001. Eur
J Clin Microbiol Infect Dis 2002;21:603—6.
9. Papa A, Christova I, Papadimitriou E, Antoniadis A. Crimean-
Congo hemorrhagic fever in Bulgaria. Emerg Infect Dis
2004;10:1465—7.
10. Papa A, Maltezou HC, Tsiodras S, Dalla VG, Papadimitriou T,
Pierroutsakos I, et al. A case of Crimean-Congo haemorrhagic
fever in Greece, June 2008. Euro Surveill 2008;13. pii: 18952.
11. Yilmaz GR, Buzgan T, Torunoglu MA, Safran A, Irmak H, Com S,
et al. A preliminary report on Crimean-Congo haemorrhagic
fever in Turkey, March—June 2008. Euro Surveill 2008;13. pii:
18953.
12. Editorial team. Increase in cases of Crimean-Congo haemorrha-
gic fever, Turkey, 2006. Euro Surveill 2006;11. pii: 3003.
13. Ergonul O, Zeller H, Kilic S, Kutlu S, Kutlu M, Cavusoglu S, et al.
Zoonotic infections among veterinarians in Turkey: Crimean-
Congo hemorrhagic fever and beyond. Int J Infect Dis
2006;10:465—9.
14. Ministry of Health of Turkey. Reports of the Communicable
Diseases Department. Ankara, Turkey: Ministry of Health; 2006.
15. European Network for Diagnostics of ‘Imported’ Viral Diseases
(ENIVD). Case definition Crimean/Congo VHF. Available at:
http://www.enivd.de/VHFDISEASES/fs_vhfdiseases.htm (ver-
sion current at November 20, 2008).
16. Yapar M, Aydogan H, Pahsa A, Besirbellioglu BA, Bodur H, Basus-
taoglu AC, et al. Rapid and quantitative detection of Crimean-
Congo hemorrhagic fever virus by one-step real-time reverse
transcriptase-PCR. Jpn J Infect Dis 2005;58:358—62.
17. Logan TM, Linthicum KJ, Moulton JR, Ksiazek TG. Antigen-cap-
ture enzyme-linked immunosorbent assay for detection and
quantification of Crimean-Congo hemorrhagic fever virus in
the tick,Hyalomma truncatum. J Virol Methods 1993;42:33—44.
18. Karti SS, Odabasi Z, Korten V, Yilmaz M, Sonmez M, Caylan R,
et al. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect
Dis 2004;10:1379—84.
19. Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran MA, Vaha-
boglu H. Crimean-Congo haemorrhagic fever outbreak in Middle
Anatolia: a multicentre study of clinical features and outcome
measures. J Med Microbiol 2005;54:385—9.
20. Ozkurt Z, Kiki I, Erol S, Erdem F, Yilmaz N, Parlak M, et al.
Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical
features, risk factors and efficacy of ribavirin therapy. J Infect
2006;52:207—15.
21. Ergonul O, Celikbas A, Baykam N, Eren S, Dokuzoguz B. Analysis
of risk-factors among patients with Crimean-Congo haemorrha-
gic fever virus infection: severity criteria revisited. Clin Micro-
biol Infect 2006;12:551—4.
22. Tonbak S, Aktas M, Altay K, Azkur AK, Kalkan A, Bolat Y, et al.
Crimean-Congo hemorrhagic fever virus: genetic analysis and
tick survey in Turkey. J Clin Microbiol 2006;44:4120—4.
23. Midilli K, Gargili A, Ergonul O, Sengoz G, Ozturk R, Bakar M, et al.
Imported Crimean-Congo hemorrhagic fever cases in Istanbul.
BMC Infect Dis 2007;7:54.
24. Engin A, Yildirim A, Kunt T, Bakir M, Dokmetas I, Ozdemir L.
Clinical investigation of the transient evoked otoacoustic emis-
sion test in Crimean-Congo hemorrhagic fever. Int J Infect Dis
2008;12:162—5.
25. Ergonul O, Akgunduz S, Kocaman I, Vatansever Z, Korten V.
Changes in temperature and the Crimean Congo hemorrhagic
e436 B. Ertugrul et al.fever outbreak in Turkey. Clin Microbiol Infect 2005;11(Suppl
2):S360.
26. Republic of Turkey Ministry of Environment and Forestry. Turkish
State Meterological Service. Available at: http://www.meteor.-
gov.tr/FILES/iklim/turkiye_iklimi.pdf (version current at
November 19, 2008).
27. Estrada-Pena A, Vatansever Z, Gargili A, Aktas M, Uzun R, Ergonul
O. Modeling the spatial distribution of Crimean-Congo hemor-
rhagic fever outbreak in Turkey. Vector Borne Zoonotic Dis
2007;7:667—78.
28. European Centre for Disease Prevention and Control. Crimean-
Congo hemorrhagic fever–—information for travellers to north-
eastern Turkey. Available at: http://www.ecdc.europa.eu (ver-
sion current at July 20, 2006).
29. Jaureguiberry S, Tattevin P, Tarantola A, Legay F, Tall A, Nabeth P,
et al. Imported Crimean-Congo hemorrhagic fever. J Clin Micro-
biol 2005;43:4905—7.
30. Leroy H, Arvieux C, Biziragusenyuka J, Chapplain JM, Guiguen C,
Michelet C, et al. A retrospective study of 230 consecutivepatients hospitalized for presumed travel-related illness
(2000—2006). Eur J Clin Microbiol Infect Dis 2008;27:1137—40.
31. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH,
Harvey S. The clinical pathology of Crimean-Congo hemorrhagic
fever. Rev Infect Dis 1989;11(Suppl 4):S794—800.
32. Peters CJ, Zaki SR. Role of the endothelium in viral hemorrhagic
fevers. Crit Care Med 2002;30(Suppl 5):S268—S273.
33. Cevik M. Kırım-Kongo Kanamali Atesi: Klinik Ozellikleri. J Klimik
2004;17:59—61.
34. van Eeden PJ, Joubert JR, van de Wal BW, King JB, de Kock A,
Groenewald JH. A nosocomial outbreak of Crimean-Congo hae-
morrhagic fever at Tygerberg Hospital. Part I. Clinical features. S
Afr Med J 1985;68:711—7.
35. Centers for Disease Control. Viral hemorrhagic fever: initial
management of suspected and confirmed cases. MMWR Morb
Mortal Wkly Rep 1983; 32(Suppl 2):27S—38S.
36. Cevik MA, Erbay A, Bodur H, Gulderen E, Bastug A, Kubar A, et al.
Clinical and laboratory features of Crimean-Congo hemorrhagic
fever: predictors of fatality. Int J Infect Dis 2008;12:374—9.
